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Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-tetrazine-8-carboxamide) is a new alkylating agent with
promising antitumour efficacy for malignant gliomas. The resistance of tumour cells to TMZ is primarily associated with levels of the
alkylguanine alkyltransferase (AGT). O
6-benzylguanine (O
6-BG), an inhibitor for AGT, reduced resistance to TMZ. Recently, it has
been demonstrated that chemosensitivity of tumour cells is related to a decline in telomerase activity. However, it is unknown if TMZ
sensitivity of malignant glioma cells correlates with telomerase. In this study, using malignant glioma cells with low levels of AGT
(U373-MG and U87-MG) and high levels of AGT (T98G), we investigated the association among AGT, telomerase, and TMZ
sensitivity. U373-MG and U87-MG cells were sensitive to TMZ (IC50 for a 2-day treatment¼100mM), while T98G cells were
resistant to TMZ (IC50 for a 2-day treatment 4500mM). Treatment with TMZ (100mM) suppressed telomerase activity in U373-MG
and U87-MG cells in a time-dependent manner, but not in T98G cells. The downregulation of telomerase activity in U373-MG and
U87-MG cells was due to inhibition of the human telomerase reverse-transcriptase (hTERT) gene expression at the transcriptional
level. This inhibitory effect was induced by interfering with transcription factor Sp1 binding sites of the hTERT core promoter.
Interestingly, O
6-BG not only sensitised T98G cells to TMZ, but also suppressed telomerase activity. These findings suggest that
response of malignant glioma cells to TMZ can be monitored by reduction in telomerase activity. Therefore, quantification of
telomerase activity during or after treatment with TMZ may be a useful marker to detect treatment efficacy.
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Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-
d]-as-tetrazine-8-carboxamide) is a new oral alkylating agent that
has recently demonstrated efficacy in the treatment of malignant
gliomas (O’Reilly et al, 1993; Plowman et al, 1994; Friedman et al,
1995, 2000; Yung et al, 1999). The cytotoxicity of TMZ is primarily
due to the formation of O
6-methylguanine in DNA, which mispairs
with thymine during the next cycle of DNA replication (Denny
et al, 1994; D’Atri et al, 1995). Subsequent futile cell cycles of DNA
mismatch repair result in cell death in cancer cells (D’Atri et al,
1998). Therefore, the sensitivity of tumour cells to TMZ is
correlated with the activity of the DNA repair protein O
6-
alkylguanine alkyltransferase (AGT), which removes alkyl groups
at the O
6 position of guanine. Cells with low levels of AGT are
sensitive to TMZ, while cells expressing high levels of AGT are
more resistant (Dolan et al, 1990; Wedge et al, 1996). O
6-
benzylguanine (O
6-BG), a potent inhibitor of AGT-mediated
resistant, enhances the activity of TMZ in tumour cells with high
levels of AGT (Dolan et al, 1990; Wedge et al, 1996).
Recently, several investigations have demonstrated that che-
motherapy-induced cell killing of tumour cells is associated with a
decline in telomerase activity (Faraoni et al, 1997; Chou et al, 2001;
Lin et al, 2001). Telomerase is a ribonucleoprotein enzyme with
reverse-transcriptase activity responsible for maintenance of
telomeric repeats onto the 30-end of chromosomes (Blackburn
et al, 1989; Harley et al, 1994). Three components of human
telomerase have been recently identified: the RNA component
(hTER) (Feng et al, 1995), the telomerase-associated protein
(TEP1) (Harrington et al, 1997; Nakayama et al, 1997), and the
telomerase reverse transcriptase (hTERT) (Meyerson et al, 1997;
Nakamura et al, 1997). Although both hTER and hTERT are
necessary for telomerase activity, hTERT is the major determinant
of telomerase activity. The vast majority of malignant tumours
express telomerase activity highly, while telomerase is not detected
in most normal cells (Kim et al, 1994; Chadeneau et al, 1995; Shay
and Wright, 1996; Hiraga et al, 1998). Therefore, telomerase is not
only a useful tumour marker, but also may be a good indicator of
chemotherapy response. However, it is unclear whether respon-
siveness of malignant glioma cells to TMZ is associated with the
level of telomerase activity.
In this study, using malignant glioma U373-MG and U87-MG
cells with low levels of AGT and T98G cells with high levels of AGT,
we assessed the link between their sensitivity to TMZ and
telomerase activity. We here demonstrate that U373-MG and
U87-MG cells were sensitive to TMG and their telomerase activity
was suppressed by blocking binding sites of transcription factor
Sp1, which is important for hTERT. In contrast, in TMZ-resistant
T98G cells, a significant decrease in telomerase activity was
undetectable. However, O
6-BG not only sensitised T98G cells to Received 10 January 2003; revised 22 May 2003; accepted 24 June 2003
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sTMZ, but also inhibited telomerase activity. Taken together, our
findings suggest that quantification of telomerase activity during
or after TMZ treatment may be a useful marker to measure the
therapeutic efficacy.
MATERIALS AND METHODS
Tumour cell lines
Human malignant glioma U373-MG, U87-MG, and T98G cells were
purchased from ATCC (American Tissue Culture Collection,
Rockville, MD, USA). Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, GIBCO BRL, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (GIBCO BRL), 4mM
glutamine, 100Uml
 1 penicillin, and 100mgml
 1 streptomycin.
U373-MG and U87-MG cells have low levels of AGT, while T98G
cells have high levels of AGT (Baer et al, 1993; Pieper et al, 1996).
Reagent
Temozolomide was kindly supplied by the Schering-Plough
Research Institute (Kenilworth, NJ, USA) and was dissolved in
DMSO (Sigma Chemical Co., St Louis, MO, USA). O
6-benzylgua-
nine was obtained from Sigma Chemical Co. and dissolved in
DMSO at 50mM stock solution.
Cell viability assay
The cytotoxic effect of TMZ on malignant glioma cell lines was
determined by using a trypan blue dye exclusion assay as
described previously (Mukai et al, 2000). Tumour cells were
seeded at 2 10
3 cells per well (0.1ml) in 96-well, flat-bottomed
plates and incubated overnight at 371C. After exposure to TMZ at
concentrations ranging from 10 to 1000mM for 2–6 days, the cells
were trypsinised and the number of viable cells was counted. The
viability of untreated cells was regarded as 100%. To investigate
the effect of O
6-BG, T98G cells were seeded at 2 10
3 cells per well
(0.1ml) in 96-well flat-bottomed plates and 24h later treated with
0.1% DMSO (control) or 50mM O
6-BG in serum-free DMEM for 2h.
After that, 100mM TMZ was added and the cells were cultured for
an additional 3 days.
Cell cycle analysis
For cell cycle analysis, tumour cells treated with or without TMZ
(100mM) for 2 or 3 days were trypsinised, stained with propidium
iodide by using the Cellular DNA Flow Cytometric Analysis
Reagent Set (Boehringer Mannheim, Indianapolis, IN, USA), and
analysed for DNA content by using the FACScan (Becton
Dickinson, San Jose, CA, USA) as described previously (Komata
et al, 2000). Data were analysed by Cell Quest software (Becton
Dickinson). Dead cells were gated out by using pulse processing.
Telomerase activity (TRAP) assay
The TRAP assay was performed with TRAPEZEt Telomerase
Detection Kit (Oncor Inc.,. Gaithernburg, MD, USA) according to the
manufacturer’s instruction with some minor modifications (Kondo
et al, 1998a). Cells (10
6) were washed once in PBS and homogenised
in 200ml of ice-cold lysis buffer (0.5% 3-[3-cholamidopropyl-
dimethylammonio]-1-propane-sulphonate (CHAPS), 10mM Tris-
HCl, pH 7.5, 1mM ethylenebis (oxyethylene-nitrilo) tetraacetic acid
(EGTA), 5mM b-mercaptoethanol, 0.1mM 4-(2-aminoethyl) benze-
nesulphonyl fluoride (AEBSF), 10% glycerol). After 30min of
incubation on ice, the lysates were centrifuged at 10000g for
15min at 41C, and the supernatant was rapidly frozen and stored at
 801C. The concentration of protein was measured using the
BioRad Protein Assay (Richmond, CA, USA). Each extract (1mg
protein) was assayed in a 50ml reaction mixture containing 10mlo f
5  TRAP Reaction Mix and 2U of Taq DNA polymerase
(Invitrogen). After a 30-min incubation at 301C for telomerase
extension, the reaction mixture was then subjected to PCR
amplification in a thermal cycler for 34 cycles at 941Cf o r3 0 s ,
551C for 30s. Then, 20ml of PCR products was applied to a 10%
polyacrylamide gel (Bio-Rad, Richmond, CA, USA) and visualised
with SYBR Green (Molecular Probe, Inc., Eugene, OR, USA)
according to the manufacturer’s instruction. The band intensity
was measured by densitometry. The extract from U373-MG cells and
the CHAPS lysis buffer were used as positive and negative control,
respectively.
RT–PCR analysis for hTR or hTERT RNA expression
The expression of hTR or hTERT mRNA was analysed by
semiquantitative RT–PCR amplification that we have more
recently described (Komata et al, 2001). The correlation between
band intensity and dose of cDNA templates was linear under the
conditions described below. RNA of each cell line treated with or
without TMZ was isolated using the RNA Isolation Kit (QIAGEN
Inc., Valencia, CA, USA). RT–PCR was performed with total RNA
(0.1mg) using the ThermoScriptt RT–PCR Kit (Invitrogen,
Carlsbad, CA, USA). The thermal cycles were: 941C for 1min,
601C for 2min, and 701C for 2min for 35 cycles for GAPDH
(450bp); 941C for 1min, 601C for 1min, and 721C for 1min for
30 cycles for hTR (126bp); and 941C for 1min, 581C for 1min,
and 721C for 1min for 30 cycles for hTERT (145bp). The primer
sets used were as follows: GAPDH, 50-CTCAGACACCATGGGGA-
AGGTGA-30 (forward) and 50-ATGATCTTGAGGCTGTTGTCATA-
30 (reverse); hTR, 50-TCTAACCCTAACTGAGAAGGGCGTAG-30
(forward) and 50-GTTTGCTCTAGAATGAACGGTGGAAG-30 (re-
verse); hTERT, 50-CGGAAGAGTGTCTGGAGCAA-30 (forward) and
50-GGATGAAGCGGAGTCTGGA-30 (reverse). The amplified pro-
ducts were fractionated on a 2% agarose gel containing 0.5mgml
 1
ethidium bromide, gels were photographed with Polaroid film
(Polaroid type 667), and photographs were quantitatively scanned
using the NIH image software. The efficiency of cDNA synthesis
from each sample was estimated by PCR with GAPDH-specific
primers.
Luciferase assay
The transcriptional activity of hTERT in malignant glioma cells
after TMZ treatment was determined by the hTERT promoter-
luciferase reporter plasmids asdescribedpreviously(Takakura et al,
1999). The structures of the hTERT promoter-luciferase constructs
are shown in Figure 4B. Various lengths of DNA fragments
upstream of the initiating ATG codon of the hTERT promoter gene
were PCR amplified and inserted into luciferase reporter vector
pGL3-Basic (Promega CORP-BTC, Madison, WI, USA). For the
construction of reporter plasmids containing substitution muta-
tions in factor binding sites of c-Myc or Sp1, site-specific
mutagenesis was performed by a PCR-based protocol as described
previously (Kyo et al, 2000). Cells were plated at a density of 5 10
4
cellsml
 1 day prior to TMZ treatment. At 1 day after exposure to
TMZ, the cells were transfected with the luciferase reporter
plasmids (0.5mg each) using GenePorter (Gene Therapy System
INC., San Diego, CA, USA) according to the manufacturer’s
instruction. At 48h after transfection, cells were washed twice with
PBS and lysed in the lysis buffer provided with the luciferase kit
(Promega CORP-BTC). Transcriptional activity was measured
using a Microtiter Plate Luminometer (Dynatech Laboratories,
Inc., Chantilly, VA, USA). To ensure that the luciferase assay was
within the linear range for samples and positive control, the
standard curve of light units vs relative enzyme concentration was
obtained by making serial dilutions of luciferase (QuantiLum
s
Recombinant Luciferase, Promega CORP-BTC) in 1  lysis buffer
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swith 1mgml
 1 BSA. The b-galactosidase reporter pCMVb (Pro-
mega CORP-BTC) was cotransfected as control for transfection
efficiency. b-Galactosidase activity was measured simultaneously
using the b-galactosidase assay kit (Promega CORP-BTC).
Statistical analysis
Cell viability, telomerase activity measured by TRAPEZE, and
relative luciferase activity represent the average of three indepen-
dent assays. Statistical differences were assessed using an unpaired
Student’s t-test comparing each data point with untreated cells. A
probability (P) o0.05 was considered significant.
RESULT
Sensitivity of malignant glioma cells to TMZ
To determine the effect of TMZ over time and increasing
concentrations, tumour cells were treated with TMZ (10–
1000mM) for 2–6 days. As shown in Figure 1, treatment with
TMZ inhibited the viability of U373-MG and U87-MG cells having
low levels of AGT in a time- and dose-dependent manner. The
CD50 (concentration resulting in cell viability of 50% of control) of
TMZ (a 2-day treatment) for U373-MG or U87-MG cells was
approximately 100mM. On the other hand, T98G cells, which have
high levels of AGT, were resistant to TMZ (Figure 1). TMZ at a
concentration of 10 or 100mM did not induce significant
antitumour effect. The inhibitory effect of TMZ (500mM) was
temporary and T98G cells started proliferating 4 days after
exposure to TMZ. Treatment with TMZ at a concentration of
1000mM inhibited the viability of T98G cells in a time-dependent
manner. The TMZ CD50 (a 2-day treatment) for T98G cells was
more than 500mM, indicating that the resistance factor is more
than five-fold. Therefore, we chose the concentration of 100mM to
treat U373-MG, U87-MG, and T98G cells for further experiments.
Effect of TMZ on cell cycle of malignant glioma cells
To determine if TMZ affects cell cycle of malignant glioma cells,
the DNA flow cytometric analysis was performed. As shown in
Figure 2, TMZ treatment (100mM) increased the cell population in
the G2/M phase from 15.9% on day 0 to 22.8% on day 2, and to
47.8% on day 3 in U373-MG cells. Similar results were observed in
TMZ-sensitive U87-MG cells (data not shown). In TMZ-resistant
T98G cells, the percentage of G2/M population was 13.8% on day 0,
19.3% on day 2, and 20.8% on day 3. These results indicate that
TMZ induced G2/M arrest in malignant glioma cells, and that the
extent of growth arrest depended on the sensitivity to TMZ.
Downregulation of telomelase activity in TMZ-sensitive
malignant glioma cells by TMZ
To investigate whether telomerase activity is affected by treatment
with TMZ, we performed the telomerase activity assay (TRAP
U87-MG T98G
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Figure 1 Sensitivity of malignant glioma cells to TMZ. Tumour cells were seeded at 2 10
3 cells per well (0.1ml) in 96-well flat-bottomed plates and
incubated overnight at 371C. After exposure to TMZ at concentrations ranging from 10 to 1000mM for 2–6 days, the cells were trypsinised and the number
of viable cells was counted. The viability of the untreated cells was regarded as 100%. The results shown are the means7s.d. of three independent
experiments.
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Figure 2 Effect of TMZ on cell cycle of U373-MG or T98G malignant glioma cells. For cell cycle analysis, tumour cells were collected 2 or 3 days after
exposure to TMZ (100mM), and stained with propium iodide and analysed in the FACScan. The percentage of cells in different phases was determined by
using Cell Quest software. The data shown are representative of three independent experiments.
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sassay). As shown in Figure 3A, telomerase activity of U373-MG and
U87-MG cells was suppressed by treatment with TMZ (100mM) for
3 days. The intensity of telomerase activity in treated U373-MG
and U87-MG cells was 10 and 15% of that in untreated tumour
cells, respectively. In contrast, there was no significant decline in
telomerase activity in T98G cells treated with TMZ (100mM). These
results indicate that inhibition of telomerase activity correlated
with the sensitivity of malignant glioma cells to TMZ.
Inhibition of hTERT mRNA expression in TMZ-sensitive
malignant glioma cells by TMZ
Since expression of hTERT mRNA is closely associated with
telomerase activity (Meyerson et al, 1997; Nakamura et al, 1997),
we examined whether hTERT mRNA expression is suppressed in
U373-MG or U87-MG cells by TMZ. As shown in Figure 3B, the
expression level of hTERT mRNA in U373-MG cells treated with
TMZ (100mM) was decreased to 67% on day 1, 19% on day 2, and
25% on day 3 compared to the baseline value. A decline in hTERT
mRNA was also detected in U87-MG cells treated with TMZ (data
not shown). In contrast, the mRNA hTERT level of T98G cells
following TMZ treatment remained unchanged. There was no
decrease of hTR expression in U373-MG or T98G cells after TMZ
treatment. These results indicate that inhibition of telomerase
activity in TMZ-sensitive cells following TMZ treatment is due to a
striking decrease in hTERT mRNA.
Inhibition of hTERT transcription in TMZ-sensitive
malignant glioma cells by TMZ
Since TMZ significantly inhibited the expression of hTERT mRNA
in U373-MG or U87-MG cells, we examined whether TMZ
suppresses the transcriptional activity of hTERT. The proximal
181bp region from a transcription start site is a core promoter of
hTERT gene for transcriptional activation (Takakura et al, 1999).
As shown in Figure 4A, transcriptional activity of hTERT gene was
decreased in U373-MG cells treated with TMZ (100mM) in a time-
dependent manner. The luciferase activity of U373-MG cells using
the p181 promoter was significantly suppressed to 45% (day 3) of
that of untreated U373-MG cells (P¼0.005). Similar results were
observed in treated U87-MG cells (data not shown). In contrast,
there was no significant reduction in transcriptional activity of
T98G cells during TMZ treatment. These results indicate that TMZ
inhibits hTERT at the transcriptional level and subsequently
downregulates telomerase activity in TMZ-sensitive malignant
glioma cells.
TMZ inhibited the transcriptional activity of hTERT
promoter via the Sp1 binding sites
The core promoter (p181) has two E-boxes that bind c-Myc and
five GC-boxes for Sp1 binding (Figure 4B). When an E-box located
at the 50-end of the core promoter was deleted (p150), reduction in
transcriptional activity was only marginal in untreated U373-MG
cells. Abrogation of two E-boxes by mutation (Myc-MT) also led to
only a slight reduction in transcriptional activity in untreated
tumour cells. On the other hand, reduction in transcriptional
activity of the p150 or Myc-MT promoter following treatment with
TMZ was still significant compared to baseline (Po0.01). These
suggest that E-boxes might not be essential for transcriptional
activation in U373-MG cells and for TMZ-induced decline in
telomerase activity. Further deletions of the core promoter p181
from  150 to  70 (p120, p100, p82, or p70) led to 60–92%
reduction in transcriptional activity in untreated U373-MG cells.
Additionally, the extent of TMZ-induced reduction in transcrip-
tional activity of these promoters was less than that of p180 or
p150 promoter. Moreover, the p47, p32, and p18 had no significant
transcriptional activity in untreated U373-MG cells. These findings
suggest that GC-boxes for Sp1 binding were more essential for
transcriptional activity in U373-MG cells than E-boxes for c-Myc,
CHAPS TMZ
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T98G
T98G
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Days
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Figure 3 Downregulation of telomerase in TMZ-sensitive cells by TMZ. (A) Effect of TMZ on telomerase activity of U373-MG, U87-MG, and T98G cells.
Telomerase activity was measured with the TRAPEZEt Telomerase Detection Kit. Tumour cells were harvested 3 days after exposure to TMZ (100mM).
Aliquots of 1mg protein extract were used for assay. The amplification products were applied to a 10% polyacrylamide gel and stained using SYBR Green.
Lysis buffer CHAPS was used as a negative control. The data shown are representative of three independent experiments. (B) Effect of TMZ on expression
of hTR or hTERT of U373-MG and T98G cells. RNA was isolated at the indicated time points from U373-MG or T98G cells treated with TMZ (100mM),
RT–PCR was performed using primer sets for hTR or hTERT mRNA expression. The PCR products were run on a 2% agarose gel containing 0.5mgml
 1
ethidium bromide. Primer sets for GAPDH were used as an internal control. The data shown are representative of three independent experiments.
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sand that TMZ might interfere with some Sp1 sites. Although
abrogation of each Sp1 site by mutation except Sp1-MT4 reduced
transcription to various extents, TMZ-induced reduction in Sp1-
MT1, -MT2, -MT4, or -MT5 was distinct. There was no significant
difference between control and TMZ treatment in Sp1-MT3.
Mutation of all Sp1 sites (Sp1-MT1–5) led to a 495% loss of
transcriptional activity in untreated U373-MG cells. These results
indicate that Sp1 sites are more important for transcriptional
activity in U373-MG cells than c-Myc sites and the reduction of
transcriptional activity induced by TMZ might be due to TMZs
interfering with Sp1 binding sites (at least Sp1 at  60).
Effect of O
6-BG on TMZ-resistant T98G cells
To investigate the effect of O
6-BG on TMZ-resistant tumour cells,
T98G cells were treated with TMZ in the presence of O
6-BG. As
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Figure 4 Inhibition of hTERT transcription in TMZ-sensitive cells by TMZ. (A) Effect of TMZ on transcriptional activity of hTERT core promoter (p181) in
U373-MG and T98G cells. At 1 day after TMZ treatment (100mM), tumour cells were transfected with 0.5mg of luciferase expressing vector driven by
hTERT core promoter using cationic lipid. At 48h after the transfection, the cells were washed, lysed, and assayed for luciferase activity. The b-galactosidase
reporter pCMVb was cotransfected as control for transfection efficiency. The relative luciferase activity of untreated U373-MG and T98G cells normalised by
b-galactosidase activity was regarded as 100%. The results shown are the means7s.d. of three independent experiments. *P¼0.005. (B) Deletion and
mutational analyses of the hTERT core promoter (p181). Luciferase reporter plasmids with serial deletions of the core promoter or substitution mutations in
the factor binding sites were prepared. Arrows indicate the mutated sites for binding factors shown above the figure. These reporter plasmids were
transfected into U373-MG cells 1 day after TMZ treatment (100mM), and luciferase assays were performed as described above. The b-galactosidase
reporter pCMVb was cotransfected as control for transfection efficiency. The relative luciferase activity of the p181 core promoter in untreated U373-MG
cells normalised by b-galactosidase activity was regarded as 100%. The results shown are the means7s.d. of three independent experiments.
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sshown in Figure 5A, O
6-BG significantly enhanced the antitumour
effect of TMZ on T98G cells (Po0.01). Treatment with TMZ
(100mM) and O
6-BG (50mM) inhibited the viability of T98G cells to
47% of the control, although O
6-BG alone showed some inhibitory
effect. Then we investigated if telomerase activity is inhibited in
T98G cells following treatment with TMZ and O
6-BG. As shown in
Figure 5B, combining TMZ with O
6-BG inhibited telomerase
activity in T98G cells. The intensity of telomerase activity in T98G
cells treated with O
6-BG alone or combining O
6-BG with TMZ was
81 or 59% of that in untreated T98G cells. Moreover, treatment
with O
6-BG alone or combination of O
6-BG with TMZ inhibited the
transcriptional activity of hTERT to 78 or 57% of the control
(Figure 5C). These results indicate that O
6-BG not only sensitised
T98G cells to TMZ, but also downregulated telomerase activity in
T98G cells treated with TMZ.
DISCUSSION
In the present study, we showed that treatment with TMZ inhibited
telomerase activity in TMZ-sensitive tumour cells by interfering
with binding sites of transcription factor Sp1. In contrast,
telomerase activity remained unchanged in TMZ-resistant tumour
cells during the treatment with TMZ. When TMZ-resistant tumour
cells were sensitised to TMZ by O
6-BG, a decline in telomerase
activity was detected. These findings suggest that response of
malignant glioma cells to TMZ can be monitored by reduction in
telomerase activity. Recent investigation showed that radiation
treatment decreases the telomerase activity in HeLa cells, which
correlated with cell death (Sawant et al, 1999). Moreover, the
decrease in telomerase activity following chemotherapy such as
vincristine or doxorubicin paralleled the decrease in cell viability
in several tumour cells (Faraoni et al, 1997; Lin et al, 2001).
Therefore, determination of telomerase activity during or after
treatment with chemotherapy or radiation may be a novel measure
for monitoring chemo- or radioresponse of tumour cells.
On the other hand, the association between telomerase activity
in untreated tumour cells and their chemosensitivity is contro-
versial. Telomerase inhibition rendered breast cancer cells more
susceptible to etoposide or doxorubicin, but not to cisplatin
(Ludwig et al, 2001). Malignant glioma cells were sensitised to
cisplatin by inhibition of telomerase (Kondo et al, 1998b).
Furthermore, inhibition of telomerase resulted in increased
sensitivity to cisplatin, but increased resistance to TMZ in
melanoma cells (Tentori et al, 2003). Therefore, the relationship
between levels of telomerase activity in tumour cells prior to
anticancer therapies and their sensitivity to therapeutic agents may
depend on the type of cell or treatment. Indeed, in the present
study, TMZ-sensitive and -resistant malignant glioma cells express
a similar high level of telomerase. As suggested by Tentori et al
(2003), TMZ sensitivity seems to be dependent mainly on
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Figure 5 Effect of O
6-BG on TMZ-resistant T98G cells. (A) Effect of
combining TMZ with O
6-BG on cell viability of T98G cells. Tumour cells
were seeded at 2 10
3 cells per well (0.1ml) in 96-well flat-bottomed
plates, and 24h later treated with 0.1% DMSO or 50mM O
6-BG for 2h. At
3 days after exposure to TMZ (100mM), the cells were trypsinised and the
number of viable cells was counted. The viability of the untreated cells was
regarded as 100%. The results shown are the means7s.d. of three
independent experiments. (B) Effect of combining TMZ with O
6-BG on
telomerase activity of T98G cells. Telomerase activity was measured with
the TRAPEZEt Telomerase Detection Kit. Tumour cells treated as
described above were harvested 3 days after exposure to TMZ (100mM).
Aliquots of 1mg protein extract were used for assay. The amplification
products were applied to a 10% polyacrylamide gel and stained using SYBR
Green. The data shown are representative of two independent experi-
ments. (C) Effect of combining TMZ with O
6-BG on transcriptional activity
of hTERT core promoter (p181) in T98G cells. At 1 day after the
treatment with TMZ (100mM) and/or O
6-BG (50mM), tumour cells were
transfected with 0.5mg of luciferase expressing vector driven by hTERT
core promoter using cationic lipid. At 48h after the transfection, the cells
were washed, lysed, and assayed for luciferase activity. The b-galactosidase
reporter pCMVb was cotransfected as control for transfection efficiency.
The relative luciferase activity of untreated T98G cells normalised by b-
galactosidase activity was regarded as 100%. The results shown are the
means7s.d. of three independent experiments.
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cells.
Regulation of telomerase activity is tightly controlled as it is
expressed in the vast majority of malignant cells and in limited
types of somatic cells (Kim et al, 1994; Chadeneau et al, 1995; Shay
and Wright, 1996; Hiraga et al, 1998). Therefore, understanding
the molecular mechanisms of telomerase activation or repression
is an important step in the development of diagnostic or
therapeutic applications. Telomerase activity is mainly regulated
by hTERT gene expression (Meyerson et al, 1997; Nakamura et al,
1997). The hTERT promoter region has a high density of CpG
dinucleotides and a number of putative transcription factor
binding sites such as Sp1 or c-Myc (Horikawa et al, 1999;
Takakura et al, 1999). Transcriptional activity of hTERT is
dependent on the proximal 181bp region of the promoter, which
is essential for transactivation in immortalised and cancer cells
(Takakura et al, 1999). This core promoter (p181) contains two E-
boxes and five GC-boxes, the consensus binding sequences for c-
Myc and Sp1, respectively. In the present study, our findings with
serial deletion or mutation assays of the p181 promoter indicated
that c-Myc sites within p181 were less important for transcrip-
tional regulation of the hTERT gene in malignant glioma cells than
Sp1 sites. A decline in telomerase activity by TMZ might result
from a diminished level or function of Sp1. Our findings were
consistent with recent investigation demonstrating that Sp1 sites
are important for human papillomavirus E2-mediated repression
of the hTERT promoter (Lee et al, 2002). On the other hand, it has
been recently demonstrated that arsenic downregulates the
promoter activity of hTERT by interfering with both c-Myc and
Sp1 binding sites (Chou et al, 2001). Although Sp1 and c-Myc
cooperatively activate hTERT expression (Kyo et al, 2000), it is
possible that TMZ or E2 directly or indirectly suppresses the
transactivation function of Sp1 itself.
Sp1 is one of the very first mammalian transcription factors
to be cloned (Kadonaga et al, 1987). It binds to GC-rich sequences
such as GC-boxes (Gidoni et al, 1985) and basic transcription
elements (Imataka et al, 1992). Additionally, Sp1 binding sites
are found in the promoters of many housekeeping genes (Black
and Azizkhan-Clifford, 1999). Therefore, it has been widely
accepted that Sp1 functions as a basal transcription factor
and Sp1 binding sites represent constitutive promoter elements
to support basal transcription in these promoters (Black
et al, 2001). Recent investigations indicate that Sp1 sites are
involved in growth regulation (Chen et al, 2000). In case of
malignant glioma cells, inhibition of Sp1 sites-dependent
transcription reduced cell growth as well as invasiveness (Ishibashi
et al, 2000). Interestingly, there is increasing evidence demonstrat-
ing the interaction of Sp1 with GC-rich sequences within
the p27
KIP1 promoter (Grinstein et al, 2000). Inhibition of
endogenous Sp1 activity by a dominant-negative Sp1 mutant
was associated with cell cycle arrest and increased level of p27
KIP1
(Grinstein et al, 2000). Since the cell cycle arrest (Figure 2) and
the increased expression of p27
KIP1 (data not shown) were
detected in TMZ-sensitive U373-MG cells following TMZ therapy,
we suggest that TMZ treatment may induce Sp1 repressors
in TMZ-sensitive cells, resulting in inhibition of telomerase
activity and increase of p27
KIP1 expression to show antitumour
efficacy.
DNA-damaging chemotherapeutic agents such as TMZ alter
DNA at the O
6 position of guanine and mediate their cytotoxicity
at this site (Gerson, 2002). O
6-alkylguanine DNA adducts are
repaired by AGT. Tumour expression of AGT activity varies and
correlates with therapeutic response to chemotherapy. Certainly,
TMZ-sensitive U373-MG or U87-MG cells express a low level of
AGT activity (Baer et al, 1993), while a high level of AGT is
detected in TMZ-resistant T98G cells (Pieper et al, 1996). Although
the AGT promoter contains Sp1 binding sites like the hTERT gene
(Pieper et al, 1996; Horikawa et al, 1999; Takakura et al, 1999), the
relationship between telomerase and AGT activity is unclear.
Several possibilities may be raised. If TMZ produces enough Sp1
repressors to suppress AGT activity in T98G cells, the tumour cells
would be sensitised to TMZ. If TMZ specifically suppresses Sp1
binding sites at the hTERT gene, the Sp1 activity of AGT gene
would remain unchanged. It is also possible that it is a result of
methylation at the G–C sequences either at guanine O
6 or cytosine
C
5, which may inhibit Sp1 binding and downregulate the hTERT
gene. Further investigations will be necessary to elucidate the
precise mechanisms.
In summary, we demonstrate that a decline in telomerase
activity by TMZ correlates with cellular sensitivity to TMZ. In
TMZ-sensitive malignant glioma cells, telomerase activity was
inhibited by treatment with TMZ. Telomerase activity of TMZ-
resistant tumour cells was suppressed by combining TMZ with O
6-
BG. Our findings suggest that the response of malignant gliomas to
TMZ therapy could be followed by determination of telomerase
levels.
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